Genmab A/S 26.08.201309:10 Dissemination of a Adhoc News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Company Announcement -- Genmabreaches milestone in DuoBody(r) platform collaboration with Janssen-- $1 millionmilestone payment to Genmab Copenhagen, Denmark; August 26, 2013- Genmab A/S(OMX: GEN) announced today it has reached another milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc.and its affiliates (' Janssen'), triggering a $1 millionpayment. The milestone is for achieving technical proof-of-concept for the second DuoBody product candidate. Under the agreement, Janssenhas the right to use the DuoBody technology to create panels of bispecific antibodies (up to 10 DuoBody programs) to multiple disease target combinations with Genmabresearch funded by Janssen. Genmabreceived an upfront payment of $3.5 million(approx. DKK 21 millionon the date of the agreement) from Janssenin July 2012and will potentially be entitled to milestone and license payments of up to approximately $175 million(approx. DKK 1,062 millionon the date of the agreement), as well as royalties for each commercialized DuoBody product. 'Reaching technical proof-of-concept is a significant accomplishment in our DuoBody platform collaboration with Janssenwhich continues apace. So far, Janssenhas activated five of the ten possible programs included in our agreement and we couldn't be more pleased with the rapid progress we're making,' said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Today's news will not impact Genmab's2013 financial guidance. About the DuoBody Platform The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies' specificity and efficacy in inactivating the disease targets. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab'sDuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.